WO2000064893A3 - Nouvel agent pharmaceutique - Google Patents

Nouvel agent pharmaceutique Download PDF

Info

Publication number
WO2000064893A3
WO2000064893A3 PCT/GB2000/001522 GB0001522W WO0064893A3 WO 2000064893 A3 WO2000064893 A3 WO 2000064893A3 GB 0001522 W GB0001522 W GB 0001522W WO 0064893 A3 WO0064893 A3 WO 0064893A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
spectrum containing
containing peaks
antidiabetic
peaks
Prior art date
Application number
PCT/GB2000/001522
Other languages
English (en)
Other versions
WO2000064893A2 (fr
Inventor
Paul David James Blackler
Robert Gordon Giles
Stephen Moore
Michael John Sasse
Original Assignee
Smithkline Beecham Plc
Paul David James Blackler
Robert Gordon Giles
Stephen Moore
Michael John Sasse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909471.6A external-priority patent/GB9909471D0/en
Priority claimed from GBGB9912195.6A external-priority patent/GB9912195D0/en
Priority to APAP/P/2001/002329A priority Critical patent/AP1607A/en
Priority to KR1020017013592A priority patent/KR100744361B1/ko
Application filed by Smithkline Beecham Plc, Paul David James Blackler, Robert Gordon Giles, Stephen Moore, Michael John Sasse filed Critical Smithkline Beecham Plc
Priority to PL00351685A priority patent/PL351685A1/xx
Priority to UA2001117940A priority patent/UA67845C2/uk
Priority to MXPA01010822A priority patent/MXPA01010822A/es
Priority to BR0009935-0A priority patent/BR0009935A/pt
Priority to NZ515167A priority patent/NZ515167A/xx
Priority to CA002370262A priority patent/CA2370262A1/fr
Priority to AU43072/00A priority patent/AU4307200A/en
Priority to EP00922793A priority patent/EP1175418A2/fr
Priority to JP2000614245A priority patent/JP2002543076A/ja
Priority to DZ003164A priority patent/DZ3164A1/fr
Priority to IL14611500A priority patent/IL146115A0/xx
Priority to SK1493-2001A priority patent/SK14932001A3/sk
Priority to EA200101122A priority patent/EA003031B1/ru
Publication of WO2000064893A2 publication Critical patent/WO2000064893A2/fr
Publication of WO2000064893A3 publication Critical patent/WO2000064893A3/fr
Priority to HR20010774A priority patent/HRP20010774A2/hr
Priority to NO20015148A priority patent/NO320587B1/no
Priority to ZA200108718A priority patent/ZA200108718B/xx
Priority to HK02104877.8A priority patent/HK1045152A1/zh
Priority to US11/458,471 priority patent/US7358366B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Forme polymorphe de 5-[4-[2-(N-méthyle-N-(2-pyridyl)amino)éthoxy]benzyl]thiazolidine-2,4-dione, sel d'acide maléique (le « polymorphe ») caractérisée par le fait qu'elle produit : (i) un spectre infrarouge contenant des crêtes à 1752, 1546, 1154, 621 et 602 cm-1; et/ou (ii) un spectre de Raman contenant des crêtes à 1751, 1243 et 602 cm-1; et/ou (iii) un spectre de résonance magnétique nucléaire par semi-conducteur contenant des crêtes à 111,9, 114,8, 119,6, 129,2, 134, 138, 144,7, 153,2, 157,1, 170,7, 172 et 175 ppm ; et/ou (iv) une configuration de diffraction de poudre aux rayons X (XRPD) produisant des espacements de réseau calculés de 6,46, 5,39, 4,83, 4,68, 3,71, 3,63, 3,58 et 3,48 Angströms ; procédé servant à préparer ce composé, composition pharmaceutique contenant ce composé et son utilisation médicale.
PCT/GB2000/001522 1999-04-23 2000-04-19 Nouvel agent pharmaceutique WO2000064893A2 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
KR1020017013592A KR100744361B1 (ko) 1999-04-23 2000-04-19 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
EA200101122A EA003031B1 (ru) 1999-04-23 2000-04-19 Новый фармацевтический препарат
JP2000614245A JP2002543076A (ja) 1999-04-23 2000-04-19 チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
EP00922793A EP1175418A2 (fr) 1999-04-23 2000-04-19 Nouvel agent pharmaceutique
PL00351685A PL351685A1 (en) 1999-04-23 2000-04-19 Novel pharmaceutical
UA2001117940A UA67845C2 (uk) 1999-04-23 2000-04-19 Поліморф 5-[4-[2- (n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
MXPA01010822A MXPA01010822A (es) 1999-04-23 2000-04-19 Composicion farmaceutica novedosa.
BR0009935-0A BR0009935A (pt) 1999-04-23 2000-04-19 Produto farmacêutico
NZ515167A NZ515167A (en) 1999-04-23 2000-04-19 Thiazolidinedione derivative and its use as antidiabetic
CA002370262A CA2370262A1 (fr) 1999-04-23 2000-04-19 Nouvel agent pharmaceutique
DZ003164A DZ3164A1 (fr) 1999-04-23 2000-04-19 Nouvel agent pharmaceutique.
APAP/P/2001/002329A AP1607A (en) 1999-04-23 2000-04-19 Thiazolidinedione derivative and its use as antidiabetic.
SK1493-2001A SK14932001A3 (sk) 1999-04-23 2000-04-19 Polymorfná forma 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoxy] benzyl]tiazolidín-2,4-diónu s kyselinou maleínovou, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
AU43072/00A AU4307200A (en) 1999-04-23 2000-04-19 Novel pharmaceutical
IL14611500A IL146115A0 (en) 1999-04-23 2000-04-19 Thiazolidinedione derivative and its use as antidiabetic
NO20015148A NO320587B1 (no) 1999-04-23 2001-10-22 Polymorf, anvendelse og fremstilling derav, samt farmasoytisk preparat.
HR20010774A HRP20010774A2 (en) 1999-04-23 2001-10-22 Thiazolidinedione derivative and its use as antidiabetic
ZA200108718A ZA200108718B (en) 1999-04-23 2001-10-23 Thiazolidinedione derivative and its use as antidiabetic.
HK02104877.8A HK1045152A1 (zh) 1999-04-23 2002-06-28 噻唑烷二酮衍生物及其用作抗糖尿病藥的應用
US11/458,471 US7358366B2 (en) 1999-04-23 2006-07-19 Thiazolidinedione derivative and its use as antidiabetic

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9909471.6 1999-04-23
GBGB9909471.6A GB9909471D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912195.6A GB9912195D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical
GB9912195.6 1999-05-25

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US3087702A Continuation 1999-04-23 2002-04-22
US10030877 A-371-Of-International 2002-04-22
US10/843,741 Continuation US20040248945A1 (en) 1999-04-23 2004-05-12 Thiazolidinedione derivative and its use as antidiabetic

Publications (2)

Publication Number Publication Date
WO2000064893A2 WO2000064893A2 (fr) 2000-11-02
WO2000064893A3 true WO2000064893A3 (fr) 2001-01-25

Family

ID=26315459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001522 WO2000064893A2 (fr) 1999-04-23 2000-04-19 Nouvel agent pharmaceutique

Country Status (36)

Country Link
EP (2) EP1277753A1 (fr)
JP (1) JP2002543076A (fr)
KR (1) KR100744361B1 (fr)
CN (1) CN1152878C (fr)
AP (1) AP1607A (fr)
AR (2) AR023750A1 (fr)
AU (2) AU4307200A (fr)
BG (1) BG65517B1 (fr)
BR (1) BR0009935A (fr)
CA (1) CA2370262A1 (fr)
CO (1) CO5170419A1 (fr)
CZ (1) CZ20013801A3 (fr)
DZ (1) DZ3164A1 (fr)
EA (1) EA003031B1 (fr)
EG (1) EG23937A (fr)
GC (1) GC0000250A (fr)
HK (1) HK1045152A1 (fr)
HR (1) HRP20010774A2 (fr)
HU (1) HUP0200937A3 (fr)
IL (1) IL146115A0 (fr)
MA (1) MA26786A1 (fr)
MX (1) MXPA01010822A (fr)
MY (1) MY138673A (fr)
NO (1) NO320587B1 (fr)
NZ (1) NZ515167A (fr)
OA (1) OA11873A (fr)
PE (1) PE20010045A1 (fr)
PL (1) PL351685A1 (fr)
SK (1) SK14932001A3 (fr)
TR (1) TR200103060T2 (fr)
TW (1) TWI288749B (fr)
UA (1) UA67845C2 (fr)
UY (1) UY26119A1 (fr)
WO (1) WO2000064893A2 (fr)
YU (1) YU75401A (fr)
ZA (1) ZA200108718B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
IL145796A0 (en) * 1999-04-13 2002-07-25 Us Health Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
EP1173435B1 (fr) 1999-04-23 2003-07-30 SmithKline Beecham plc Nouvelle forme polymorphe du sel d'acide 5- 4- 2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione,maleique
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2004062667A1 (fr) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Forme amorphe du maleate de rosiglitazone et procede de preparation
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (fr) * 2003-04-18 2004-11-03 CHEMI S.p.A. Formes polymorphes de maléate de rosiglitatone
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
TW201336497A (zh) * 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd 噻唑啶二酮化合物之結晶型及其製法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005659A1 (fr) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Derives substitues de la thiazolidenedione
WO1999031094A1 (fr) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Produit pharmaceutique consistant en un hydrate, sel de l'acide maleique, de formule 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione
WO1999031093A1 (fr) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Derive substitue de la thiazolidinedione son procede de preparation et ses emplois en pharmacie
WO1999031095A1 (fr) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Produit pharmaceutique constitue par un hydrate, sel de l'acide maleique, de formule 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005659A1 (fr) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Derives substitues de la thiazolidenedione
WO1999031094A1 (fr) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Produit pharmaceutique consistant en un hydrate, sel de l'acide maleique, de formule 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione
WO1999031093A1 (fr) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Derive substitue de la thiazolidinedione son procede de preparation et ses emplois en pharmacie
WO1999031095A1 (fr) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Produit pharmaceutique constitue par un hydrate, sel de l'acide maleique, de formule 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HALEBLIAN J ET AL: "Pharmaceutical application of polymorphism", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 58, no. 8, 1 August 1969 (1969-08-01), pages 911 - 929, XP002020518, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
TR200103060T2 (tr) 2002-05-21
HUP0200937A2 (en) 2002-08-28
EG23937A (en) 2008-01-14
KR100744361B1 (ko) 2007-07-30
IL146115A0 (en) 2002-07-25
NZ515167A (en) 2004-02-27
AU2755102A (en) 2002-05-16
NO20015148L (no) 2001-12-17
CN1152878C (zh) 2004-06-09
CZ20013801A3 (cs) 2002-07-17
ZA200108718B (en) 2002-12-03
AP2001002329A0 (en) 2001-12-31
CN1355800A (zh) 2002-06-26
HRP20010774A2 (en) 2002-10-31
AR023750A1 (es) 2002-09-04
PE20010045A1 (es) 2001-03-10
BG106122A (en) 2002-05-31
MXPA01010822A (es) 2002-06-04
AR023560A1 (es) 2002-09-04
CO5170419A1 (es) 2002-06-27
AP1607A (en) 2006-05-03
AU771342B2 (en) 2004-03-18
EP1277753A1 (fr) 2003-01-22
UA67845C2 (uk) 2004-07-15
AU4307200A (en) 2000-11-10
YU75401A (sh) 2004-09-03
BG65517B1 (bg) 2008-10-31
SK14932001A3 (sk) 2002-02-05
KR20010110804A (ko) 2001-12-13
EA003031B1 (ru) 2002-12-26
PL351685A1 (en) 2003-06-02
DZ3164A1 (fr) 2000-11-02
OA11873A (en) 2006-03-27
UY26119A1 (es) 2000-12-29
WO2000064893A2 (fr) 2000-11-02
HUP0200937A3 (en) 2004-03-29
TWI288749B (en) 2007-10-21
JP2002543076A (ja) 2002-12-17
MA26786A1 (fr) 2004-12-20
NO320587B1 (no) 2005-12-27
CA2370262A1 (fr) 2000-11-02
EA200101122A1 (ru) 2002-04-25
BR0009935A (pt) 2002-04-16
HK1045152A1 (zh) 2002-11-15
EP1175418A2 (fr) 2002-01-30
MY138673A (en) 2009-07-31
GC0000250A (en) 2006-11-01
NO20015148D0 (no) 2001-10-22

Similar Documents

Publication Publication Date Title
NZ515168A (en) Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
WO2000064892A3 (fr) Nouvelle composition pharmaceutique
WO2000064893A3 (fr) Nouvel agent pharmaceutique
BG104606A (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
MY135612A (en) Novel pharmaceutical
AP1441A (en) Hydrate of 5- [4-{2-(N-methlyl-N-(2-pyridil) amino) ethoxy} benzyl] thiazolidine-2,4-dione maleic acid salt.
WO2000063205A3 (fr) Nouveau compose pharmaceutique
NZ515164A (en) Thiazolidinedione derivative and its use as antidiabetic
ECSP003436A (es) Nuevos compuestos
ECSP003437A (es) Nuevos compuestos

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809054.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 14932001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: P20010774A

Country of ref document: HR

Ref document number: PV2001-3801

Country of ref document: CZ

Ref document number: IN/PCT/2001/00973/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2370262

Country of ref document: CA

Ref document number: 2370262

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 614245

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200108718

Country of ref document: ZA

Ref document number: 1020017013592

Country of ref document: KR

Ref document number: PA/a/2001/010822

Country of ref document: MX

Ref document number: 2001/03060

Country of ref document: TR

Ref document number: DZP2001000022

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1200101040

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 515167

Country of ref document: NZ

Ref document number: 2000922793

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 106122

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200101122

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020017013592

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000922793

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10030877

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2001-3801

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2073/DELNP/2003

Country of ref document: IN

WWW Wipo information: withdrawn in national office

Ref document number: 2000922793

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017013592

Country of ref document: KR